Suppr超能文献

Akt和SCFFbw7信号通路对DAB2IP的负调控

Negative regulation of DAB2IP by Akt and SCFFbw7 pathways.

作者信息

Dai Xiangping, North Brian J, Inuzuka Hiroyuki

机构信息

Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

出版信息

Oncotarget. 2014 May 30;5(10):3307-15. doi: 10.18632/oncotarget.1939.

Abstract

Deletion of ovarian carcinoma 2/disabled homolog 2 (DOC-2/DAB2) interacting protein (DAB2IP), is a tumor suppressor that serves as a scaffold protein involved in coordinately regulating cell proliferation, survival and apoptotic pathways. DAB2IP is epigenetically down-regulated in a variety of tumors through the action of the histone methyltransferase EZH2. Although DAB2IP is transcriptionally down-regulated in a variety of tumors, it remains unclear if other mechanisms contribute to functional inactivation of DAB2IP. Here we demonstrate that DAB2IP can be functionally down-regulated by two independent mechanisms. First, we identified that Akt1 can phosphorylate DAB2IP on S847, which regulates the interaction between DAB2IP and its effector molecules H-Ras and TRAF2. Second, we demonstrated that DAB2IP can be degraded in part through ubiquitin-proteasome pathway by SCF(Fbw7). DAB2IP harbors two Fbw7 phosho-degron motifs, which can be regulated by the kinase, CK1δ. Our data hence indicate that in addition to epigenetic down-regulation, two additional pathways can functional inactivate DAB2IP. Given that DAB2IP has previously been identified to possess direct causal role in tumorigenesis and metastasis, our data indicate that a variety of pathways may pass through DAB2IP to govern cancer development, and therefore highlight DAB2IP agonists as potential therapeutic approaches for future anti-cancer drug development.

摘要

卵巢癌2/失活同源物2(DOC-2/DAB2)相互作用蛋白(DAB2IP)的缺失是一种肿瘤抑制因子,作为一种支架蛋白参与协调调节细胞增殖、存活和凋亡途径。通过组蛋白甲基转移酶EZH2的作用,DAB2IP在多种肿瘤中发生表观遗传下调。尽管DAB2IP在多种肿瘤中存在转录下调,但尚不清楚是否有其他机制导致DAB2IP功能失活。在此,我们证明DAB2IP可通过两种独立机制发生功能下调。首先,我们发现Akt1可使DAB2IP的S847位点磷酸化,这调节了DAB2IP与其效应分子H-Ras和TRAF2之间的相互作用。其次,我们证明DAB2IP可部分通过SCF(Fbw7)泛素-蛋白酶体途径降解。DAB2IP含有两个Fbw7磷酸化降解基序,可受激酶CK1δ调节。因此,我们的数据表明,除了表观遗传下调外,还有另外两条途径可使DAB2IP功能失活。鉴于DAB2IP先前已被确定在肿瘤发生和转移中具有直接因果作用,我们的数据表明多种途径可能通过DAB2IP来控制癌症发展,因此强调DAB2IP激动剂作为未来抗癌药物开发的潜在治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/611c/4102811/7c282ac163db/oncotarget-05-3307-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验